Additional								Total
		Common Stock								Paid-in				Accumulated				Stockholders'
		Shares				Amount				Capital				Deficit				Deficit
Balances, September 30, 2018			62,166,309			$	62,168			$	91,043,622			$	(97,548,971	)		$	(6,443,181	)
Stock-based compensation			-				-				815,418				-				815,418
Fair value of warrants issued to consultants			-				-				1,501				-				1,501
Shareholder surrender of shares for no consideration			(299,990	)			(299	)			299				-				-
Net loss			-				-				-				(4,161,432	)			(4,161,432	)
Balances, December 31, 2018			61,866,319			$	61,869			$	91,860,840			$	(101,710,403	)		$	(9,787,694	)

										Additional								Total
		Common Stock								Paid-in				Accumulated				Stockholders'
		Shares				Amount				Capital				Deficit				Deficit
Balances, June 30, 2017			49,228,640			$	49,230			$	72,800,699			$	(64,321,962	)		$	8,527,967
Issuance of common stock, net of issuance costs of $60,000			4,500,000				4,500				4,435,500								4,440,000
Stock-based compensation			-				-				1,507,699				-				1,507,699
Fair value of warrants issued to consultants			-				-				14,847				-				14,847
Net loss			-				-				-				(6,684,612	)			(6,684,612	)
Balances, September 30, 2017			53,728,640				53,730				78,758,745				(71,006,574	)			7,805,901
Stock-based compensation			-				-				1,194,029				-				1,194,029
Fair value of warrants issued to consultants			-				-				520,455				-				520,455
Commitment fee for issuance of common stock			344,669				345				(345	)			-				-
Net loss			-				-				-				(5,718,587	)			(5,718,587	)
Balances, December 31, 2017			54,073,309			$	54,075			$	80,472,884			$	(76,725,161	)		$	3,801,798

In December 2018, two New Investors expressed interest in investing in the Company and affirmed their intent to enter into exclusive diligence and negotiations regarding a potential equity financing (“Transaction”). In exchange for the receipt of a total million ("Exclusivity Payment"), the Company entered into an exclusivity agreement ("Exclusivity") with the New Investors. Pursuant to the terms of the Exclusivity, until the earlier to occur of: (i) the execution of a definitive agreement regarding a Transaction; (ii) the New Investors terminating the Exclusivity; or (iii) December 21, 2018, the Company agreed to cease any and all discussions and negotiations with all other third parties. In the event that both or either New Investor elected not to enter into a Transaction, then at such New Investors' sole election, it had the ability to either: (a) request that the Company refund the applicable Exclusivity Payment; or (b) elect to convert the applicable Exclusivity Payment into shares of the Company's Common Stock at a price per share to be agreed upon. As discussed in Note 11, on January 7, 2019, the New Investors decided to proceed with consummation of the Transaction whereby closing occurred on January 30, 2019. Since the Exclusivity Payment was refundable at the New Investors’ option, it is classified as a liability in the accompanying unaudited condensed consolidated balance sheet as of December 31, 2018. Since the Transaction closed on January 30, 2019, the Exclusivity Payment did not require existing working capital which results in classification as a long-term liability as of December 31, 2018.